|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/04/22 Incyte Corp. 8-K:5 9/28/22 10:185K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 28K 5: R1 Cover HTML 45K 8: XML IDEA XML File -- Filing Summary XML 11K 6: XML XBRL Instance -- tm2227007d1_8k_htm XML 14K 7: EXCEL IDEA Workbook of Financial Reports XLSX 8K 3: EX-101.LAB XBRL Labels -- incy-20220928_lab XML 96K 4: EX-101.PRE XBRL Presentations -- incy-20220928_pre XML 64K 2: EX-101.SCH XBRL Schema -- incy-20220928 XSD 12K 9: JSON XBRL Instance as JSON Data -- MetaLinks 25± 32K 10: ZIP XBRL Zipped Folder -- 0001104659-22-105577-xbrl Zip 15K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i September 28, 2022
(Exact name of registrant as specified in its charter)
| i Delaware (State or Other Jurisdiction of Incorporation) |
i 001-12400 (Commission File Number) |
i 94-3136539 (I.R.S. Employer Identification No.) |
| i 1801 Augustine Cut-Off | ||
| i Wilmington, i DE | i 19803 | |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| i ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| i ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| i ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| i ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| i Common Stock, $.001 par value per share | i INCY | i The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
C:
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Election of Directors
Effective October 1, 2022, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Susanne Schaffert, Ph.D., a member of the Board of Directors of the Company.
Dr. Schaffert, age 55, previously spent 26 years at the pharmaceutical company Novartis AG, where she served in various roles. Most recently Dr. Schaffert served as President of Novartis Oncology from January 2019 until April 2022. Prior to that role, Dr. Schaffert served from January 2018 to February 2019 as President and Chair of Accelerated Advanced Applications and from December 2012 to January 2018 as General Manager Region Europe, Novartis Oncology. From March 2010 to December 2012, Dr. Schaffert was Global Head of Investor Relations, and before that, Dr. Schaffert served as Global Franchise Head for Immunology and Transplantation. Dr. Schaffert first joined Novartis Germany in 1995 and held a series of positions in sales and marketing with increasing responsibilities in national, regional and global functions. Dr. Schaffert is also a member of the board of directors of Rubius Therapeutics, Inc.
There is no arrangement or understanding between Dr. Schaffert and any other person pursuant to which she was selected as a director of the Company, and there is no family relationship between Dr. Schaffert and any of the Company’s other directors or executive officers. The Company is not aware of any transaction involving Dr. Schaffert requiring disclosure under Item 404(a) of Regulation S-K under the Securities Act of 1933.
As a non-employee member of the Board of Directors of the Company, Dr. Schaffert will be entitled to receipt of the same cash and equity compensation paid by the Company to each of its non-employee directors, as described in the Company’s proxy statement for its 2022 Annual Meeting of Stockholders filed on April 29, 2022.
C:
| C: 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 4, 2022
| INCYTE CORPORATION | ||
| By: | /s/ Maria E. Pasquale | |
| Maria E. Pasquale | ||
| Executive Vice President and General Counsel | ||
C:
| 3 |
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 10/4/22 | |||
| 10/1/22 | ||||
| For Period end: | 9/28/22 | |||
| 4/29/22 | DEF 14A, DEFA14A | |||
| List all Filings | ||||